open access

Vol 10, Supp. C (2019)
Case report
Get Citation

The role of brentuximab vedotin in the treatment of patients with refractory/relapsed Hodgkin lymphoma based on two case reports

Monika Chełstowska1, Krzysztof Jamroziak1, Ewa Lech-Marańda1, Krzysztof Warzocha1
DOI: 10.5603/Hem.2019.0024
Affiliations
  1. Klinika Hematologii, Instytut Hematologii i Transfuzjologii, ul. Indiry Gandhi 14, 02–776 Warszawa, Poland

open access

Vol 10, Supp. C (2019)
CASE REPORTS

Abstract

Hodgkin lymphoma (HL) is a form of lymphoma with good prognosis in the majority of patients, who are cured after first line chemotherapy. However, in about 25–30% of patients, the course of the disease is unfavorable and patients require treatment of subsequent lines. In further treatment, intensive polychemotherapy is used, consolidated with hematopoietic stem cell transplantation (autologous or allogenic). Also new drugs are wanted. Immunotherapy is promising, including antibodies against CD30 — brentuximab vedotin, and antibodies, that affect the PD1/PD-L1 and PD-L2 pathways — nivolumab, pembrolizumab. Determining the optimal management of patients with relapse and refractory HL requires further investigation.

Abstract

Hodgkin lymphoma (HL) is a form of lymphoma with good prognosis in the majority of patients, who are cured after first line chemotherapy. However, in about 25–30% of patients, the course of the disease is unfavorable and patients require treatment of subsequent lines. In further treatment, intensive polychemotherapy is used, consolidated with hematopoietic stem cell transplantation (autologous or allogenic). Also new drugs are wanted. Immunotherapy is promising, including antibodies against CD30 — brentuximab vedotin, and antibodies, that affect the PD1/PD-L1 and PD-L2 pathways — nivolumab, pembrolizumab. Determining the optimal management of patients with relapse and refractory HL requires further investigation.

Get Citation

Keywords

Hodgkin lymphoma, refractory, relapsed, brentuximab vedotin, hematopoietic stem cell transplantation, case reports

About this article
Title

The role of brentuximab vedotin in the treatment of patients with refractory/relapsed Hodgkin lymphoma based on two case reports

Journal

Hematology in Clinical Practice

Issue

Vol 10, Supp. C (2019)

Article type

Case report

Pages

7-16

DOI

10.5603/Hem.2019.0024

Keywords

Hodgkin lymphoma
refractory
relapsed
brentuximab vedotin
hematopoietic stem cell transplantation
case reports

Authors

Monika Chełstowska
Krzysztof Jamroziak
Ewa Lech-Marańda
Krzysztof Warzocha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.